DE Burlo Group Inc. Sells 300 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

DE Burlo Group Inc. reduced its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 3.5% during the 3rd quarter, Holdings Channel.com reports. The institutional investor owned 8,390 shares of the biopharmaceutical company’s stock after selling 300 shares during the quarter. Regeneron Pharmaceuticals comprises about 1.1% of DE Burlo Group Inc.’s portfolio, making the stock its 26th largest holding. DE Burlo Group Inc.’s holdings in Regeneron Pharmaceuticals were worth $8,820,000 at the end of the most recent quarter.

Other hedge funds also recently made changes to their positions in the company. Brown Lisle Cummings Inc. lifted its position in shares of Regeneron Pharmaceuticals by 18.2% in the 2nd quarter. Brown Lisle Cummings Inc. now owns 65 shares of the biopharmaceutical company’s stock worth $68,000 after purchasing an additional 10 shares during the period. Sachetta LLC boosted its holdings in Regeneron Pharmaceuticals by 71.4% during the 2nd quarter. Sachetta LLC now owns 24 shares of the biopharmaceutical company’s stock worth $26,000 after acquiring an additional 10 shares during the last quarter. Adirondack Trust Co. boosted its holdings in Regeneron Pharmaceuticals by 2.4% during the 3rd quarter. Adirondack Trust Co. now owns 431 shares of the biopharmaceutical company’s stock worth $453,000 after acquiring an additional 10 shares during the last quarter. UMB Bank n.a. boosted its holdings in shares of Regeneron Pharmaceuticals by 1.1% in the 3rd quarter. UMB Bank n.a. now owns 908 shares of the biopharmaceutical company’s stock worth $955,000 after buying an additional 10 shares during the last quarter. Finally, Western Financial Corp CA boosted its holdings in shares of Regeneron Pharmaceuticals by 0.7% in the 2nd quarter. Western Financial Corp CA now owns 1,819 shares of the biopharmaceutical company’s stock worth $1,912,000 after buying an additional 12 shares during the last quarter. 83.31% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at Regeneron Pharmaceuticals

In other news, CFO Christopher R. Fenimore sold 5,680 shares of the stock in a transaction that occurred on Wednesday, August 28th. The stock was sold at an average price of $1,205.33, for a total transaction of $6,846,274.40. Following the completion of the transaction, the chief financial officer now directly owns 15,305 shares of the company’s stock, valued at approximately $18,447,575.65. This represents a 27.07 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. 7.48% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

REGN has been the topic of several recent research reports. Piper Sandler dropped their price objective on shares of Regeneron Pharmaceuticals from $1,242.00 to $1,195.00 and set an “overweight” rating on the stock in a report on Friday, November 1st. Wolfe Research assumed coverage on Regeneron Pharmaceuticals in a research note on Friday, November 15th. They set an “outperform” rating and a $1,150.00 price objective for the company. StockNews.com downgraded Regeneron Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Monday, November 4th. Barclays dropped their target price on Regeneron Pharmaceuticals from $1,080.00 to $1,065.00 and set an “overweight” rating on the stock in a research report on Friday, November 1st. Finally, BMO Capital Markets lowered their price target on Regeneron Pharmaceuticals from $1,300.00 to $1,190.00 and set an “outperform” rating on the stock in a report on Friday, November 1st. One research analyst has rated the stock with a sell rating, four have issued a hold rating, eighteen have issued a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $1,099.55.

Regeneron Pharmaceuticals Stock Down 0.2 %

Shares of NASDAQ REGN opened at $743.35 on Thursday. The business has a 50-day moving average price of $961.76 and a 200 day moving average price of $1,030.14. The company has a quick ratio of 4.46, a current ratio of 5.28 and a debt-to-equity ratio of 0.09. The stock has a market cap of $81.69 billion, a PE ratio of 18.40, a price-to-earnings-growth ratio of 2.81 and a beta of 0.15. Regeneron Pharmaceuticals, Inc. has a 52-week low of $736.01 and a 52-week high of $1,211.20.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.